William Blair research analyst Andy Hsieh was quoted in Investor’s Business Daily as he highlighted his perspective on Viking Therapeutics and its experimental obesity drug.
"We are positively surprised by the exploration of an oral tablet formulation, which we view as an alternative to a weekly subcutaneous (shot)," he said in his note to clients.